Investors are showing higher expectation for Samsung Bioepis, a Samsung Group unit that has secured the licenses to make four biosimilars out of top 10 selling drugs in the world.After Samsung Bioepis삼성바이오에피스 won the approval of European regulators for its SB3, a copy of Swiss drugmaker Roche’s breast cancer drug Herceptin, the company is likely to receive additional European approvals on its
“Knowledge” is the most important element for people engaged in bio and healthcare industry, a survey showed, reflecting the sector’s characteristics of having to come up with the state-of-the-art product. According to the inquiry of 300 companies regarding turnover conducted by Korea Institute of S&T Evaluation and Planning(KISTEP)한국과학기술기획평가원, the respondents cited the growing demand for “kno
Before the announcement of the “third draft to enhance biotechnology,” experts put forth a slew of calls for more specific, practical action programs.They voiced out the government has to change the environment of the bio industry, during a forum at the National Assembly Friday, organized by the Ministry of Science and ICT(MSIT)과학기술정보통신부.Eight cabinet ministries are to announce the draft l
New venture capital investments in bio and medical industries have fallen more sharply than any other sectors this year.According to an analysis of investment in the first seven months of this year based on the data of Korea Venture Capital Association한국벤처캐피탈협회, the VC investment in bio and medical sectors fell 26 percent from a year ago to 169.5 billion won ($150 million).The total in
Australia has emerged as the promising market for Korean medical equipment manufacturers by increasing its healthcare budget this year, following China whose medical equipment market has been expanding every year, trade experts said. The demands for expensive medical equipment are likely to surge in the two countries, which rely on import to meet most of the demands, they added. According
Local stock analysts’ eyes are now on the profit-sharing structure of the Celltrion Group. The biosimilar maker has recently released Remsima (component: infliximab) in the U.S. market and is waiting for approval to sell a breast cancer therapy Herzuma (trastuzumab) and a blood cancer therapy Truxima (rituximab) by 2019. Samsung Securities삼성증권 said if Celltrion’s sales are 100, those of Celltr
Korean drugmakers have set out to use virtual reality programs to promote and sell their products.Pharmaceutical companies introduced VR devices to explain the treatment mechanism of hypercholesterolemia at a conference hosted by Korean Society of Lipid & Atherosclerosis (KSoLA)한국지질•동맥경화학회 in the Conrad Seoul Friday and Saturday.In the conference, Chong Kun Dang Pharmaceutical종근당, which bo
Korean Society of Lipid & Atherosclerosis (KSoLA) has come out to emphasize the need for people in the 30s and 40s to control cholesterol.The society stressed the importance of controlling cholesterol as the most dangerous element in cardiovascular and cerebrovascular diseases and its treatment through drugs, in a press meeting on the sidelines of International Conference on Lipid & Atheroscle
It is urgent for the government to invest in the construction of Good Manufacturing Practice (GMP) facility to commercialize the technology for cell therapies and genetic therapies, a report says. This is because the private sector will experience difficulties establishing the GNP facility of international standards, which is a prerequisite for exporting the technology developed by the domesti
Chong Kun Dang Pharmaceutical종근당(CEO: Kim Young-joo 김영주) and MSD Korea 한국MSD(CEO: Avi BenShoshan) have introduced a virtual reality program, called “Januvia VR detail” as part of marketing strategy of their diabetes therapy.The program provides a variety of clinical data of type-2 diabetes patients for doctors with VR equipment and helps medical professionals make use of it in real situations.
Seoul National University서울대학교, Catholic University of Korea가톨릭대학교, and School of Medicine, Sungkyunkwan University성균관의대 have actively conducted researches in the stem cell therapy over the past decade, a report said.Coordination Center for Global Innovative Biotherapeutics글로벌 첨단바이오의약품 코디네이팅센터 and Postech Biotech Center생명공학연구센터 counted the number of papers related to stem cell therapies -- pub
Amid escalating North Korea risks caused by the North’s nuclear and missile provocations following the U.S. verbal attacks, bio and pharmaceutical stocks are facing both favorable and unfavorable factors because of expectations about the “Mooncare.” Some market watchers predict bio and pharmaceutical stocks will benefit from sharply expanded insurance coverage as pledged by the Moon Jae-in adm
What makes Chinese tourists come to Korea for cosmetic surgery to account for the largest portion of foreign visitors to do so?A recent paper has drawn the industry’s attention by attempting to answer the question analyzing Chinese people’s motivation for embarking on medical tourism to do plastic surgery, including their internal and external values. Professor Kim Eun-hee 김은희 of Mokwon U
Artificial intelligence such as rote learning is expected to boost success rates in clinical trials.The Research Institute for Biological Science and Technology recently said in a report that “machine learning and Robotics Processes Automation(RPA) will optimize clinical trials in the future."Processing new information and RPAs that were once a responsibility for humans are now being a
Ferring Pharmaceuticals has recently been conned out of tens of millions of won, depositing goods payment at a false account deceived by an email pretending to be its headquarter office.According to the pharmaceutical industry and the police, Ferring페링제약got an email from its headquarters telling its bank account changed and sent tens of millions of won in product payment to the account. Be
Korea, U.S., and Japanese pharmaceutical industries recorded trade deficits, while those of Germany, France, and the United Kingdom marked surpluses last year, too, a state agency said.Korea Institute of Science and Technology Evaluation and Planning(KISTEP)한국과학기술기획평가원 Thursday released its report on the trade balances of pharmaceuticals in major countries, based on statistics from the Organiz
The competition among quadrivalent products is increasingly intensifying in the domestic influenza vaccine market.In addition to six vaccine brands -- Fluarix Tetra by GSK, GC Fluquadribalant by Green Cross 녹십자, SKY Cellflu Quadrivalent by SK Chemical SK케미칼, BoryungⅴTetra Vaccine by Borung Biopharma보령바이오파마, Kovax flu 4ga PF by Korea Vaccine한국백신, and Teratect by Il-Yang Pharm 일양약품 –– that won a
Korea’s bio businesses cite “lack of R&D investment” as the main reason for their technological level lagging behind advanced countries. The Export-Import Bank of Korea surveyed 53 bio pharmaceutical companies in April and May and released its results recently.Asked why Korea’s bio technology is lower compared with advanced countries, the respondents cited the lack of R&D investment (5
GSK has released Triumeq Tab. to treat human immunodeficiency virus(HIV), drawing market watchers attention whether the new drug featuring ease of use will change the market trend in Korea which has a strong bias against AIDS. Gilead길리어드, which has market-leading treatment Stribild Tab., is about to switch to Genvoya Tab. with fewer side effects.GSK is emphasizing patients has only to take
The recent decision by Celltrion, Korea’s most successful biosimilar maker, to be listed on the Korea Stock Exchange (KRX) is attracting investors’ interestsOn Monday, minority shareholders with equity of 3 percent or more presented a notice to Celltrion셀트리온 to hold an extraordinary shareholders’ meeting to discuss the company’s listing on the KOSPI (Korea Stock Price Index) market, obligating